A growing body of evidence supports that aerobic exercise can decrease the risk of future cognitive impairment and Alzheimer's disease (AD). 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
A growing body of evidence supports that aerobic exercise can decrease the risk of future cognitive impairment and Alzheimer's disease (AD). 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Recently, transfer learning has been successfully applied in early diagnosis of Alzheimer's Disease (AD) based on multi-domain data. 1 key finding →
Participants: 807 Evidence: low
Full summary, score breakdown and related studies → Original source
Behavioral and social research has stressed the importance of multi-domain lifestyle interventions to prevent, delay, or remedy age-related cognitive decline among older adults at high risk for dementia. 2 key findings →
Participants: 59 Evidence: low
Full summary, score breakdown and related studies → Original source
Hearing loss is an important risk factor for the development of dementia, particularly Alzheimer's disease (AD). 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Genetically determined CSHL was associated with an elevated risk of DLB (odds ratio [OR] 1.69; 95% CI 1.08 to 2.63; P = 0.021) and FTD (OR 1.66; 1.04 to 2.67; P = 0.035), but not AD (P = 0.958). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Donepezil is a central-acting acetylcholinesterase inhibitor aimed at increasing acetylcholine availability at the neuron synapses to enhance cholinergic transmission. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Moderate/severe hearing loss was significantly associated with lower composite z score in males (β = -28.67, 95% confidence interval [95% CI] = -57.13 to -0.20) but not in females (β = -8.82, 95% CI = -36.61 to 18.96). 3 key findings →
Participants: 655 Evidence: low
Full summary, score breakdown and related studies → Original source
Metabolic syndrome (MetS) or otherwise insulin resistance (IR) is described as a cluster of several commonly occurring disorders, including abdominal obesity; lipids disorders, such as hypertriglyceridemia; and low levels of high-density-lipoprotein cholesterol (HDL-C), hypertension (≥130/85 mmHg), and carbohydrates disorders, such as impaired fasting glucose or diabetes mellitus type 2. 1 key finding →
Participants: 90 Evidence: low
Full summary, score breakdown and related studies → Original source
Age and comorbidities are key indicators of hospital admission, serious illness, and mortality in COVID-19 patients. 1 key finding →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source
In a sample of 2,398,405 patients receiving primary care, the target population relevant for dementia prevention measures in 2018 consisted of 191,883 patients with hypertension, 23,308 with obesity, 5,059 with hearing loss, 120,200 with diabetes and 43,233 with depression. 5 key findings →
Participants: 51 Evidence: low
Full summary, score breakdown and related studies → Original source
When risk factor p-values were FDR-adjusted, diastolic blood pressure was significantly associated with mean perfusion. 5 key findings →
Participants: 330 Evidence: low
Full summary, score breakdown and related studies → Original source
The overall weighted PAF for modifiable risk factors was 45.8% (42.2% to 49.3%). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We found that some speech parameters of frequencies and syllabic rhythm vary due to these pathologies. 5 key findings →
Participants: 40 Evidence: low
Full summary, score breakdown and related studies → Original source
CR score was dose-dependently associated with disability/death (hazard ratio [HR] 0.96, 95% confidence interval [CI] 0.93-0.99). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
TL was significantly shorter in the LLD compared with control participants (p = .039). 5 key findings →
Participants: 78 Evidence: low
Full summary, score breakdown and related studies → Original source
Diet is an important nonpharmacological risk-modifying factor for Alzheimer's disease (AD). 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Polyphenols, folate, vitamin D, omega-3 fatty acids, and β-carotene might decrease the risk of dementia. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) and vascular dementia (VaD) are the two commonest causes of dementia in older adults and frequently coexist as mixed neurodegenerative-cerebrovascular pathology. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Chlamydia pneumoniae is an intracellular bacterium implicated in Alzheimer's disease (AD), but its role in retinal pathology and disease progression is unclear. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is marked by amyloid-β (Aβ) accumulation, tau pathology, and neuroinflammation. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Peripheral immune cell infiltration and crosstalk with brain-resident cells critically drive Alzheimer's disease (AD)-associated neuroinflammation, highlighting its therapeutic potential. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD), is a chronic age-related progressive neurodegenerative disorder, characterized by neuroinflammation and extracellular aggregation of Aβ peptide. 3 key findings →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source
No differences were found between regions of interest in CAA compared to NC. 4 key findings →
Participants: 21 Evidence: low
Full summary, score breakdown and related studies → Original source
We included 110 patients with CAA (strictly lobar ICHs/CMBs), 33 with HA (strictly deep ICHs/CMBs) and 97 with mixed lobar/deep ICHs/CMBs. 5 key findings →
Participants: 110 Evidence: low
Full summary, score breakdown and related studies → Original source
We used an autopsy series to determine whether the newest dementia with Lewy bodies (DLB) consensus pathologic classification correlates with premortem diagnosis of DLB. 1 key finding →
Participants: 95 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →